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Abstract Adrenocortical carcinoma (ACC) is a rare, hetero-
geneous malignancy with a poor prognosis. According to
WHO classification 2004, ACC variants include oncocytic
ACCs, myxoid ACCs and ACCs with sarcomatous areas.
Herein, we provide a comprehensive review of these rare
subtypes of adrenocortical malignancy and emphasize their
clinicopathological features with the aim of elucidating
aspects of diagnostic categorization, differential diagnostics
and biological behavior. The issue of current terminology,
applied to biphasic tumors with pleomorphic, sarcomatous or
sarcomatoid elements arising in adrenal cortex, is also
discussed. We additionally present emerging evidence
concerning the adrenal cortical tumorigenesis and the putative
adenoma–carcinoma sequence as well.
Keywords Adrenal cortical neoplasia.Adenoma.
Carcinoma.ACC variants.Oncocytic.Myxoid.
Sarcomatoid.Carcinosarcoma
Introduction
Adrenocortical carcinoma (ACC) is a rare heterogeneous
malignancy with an incidence of 0.7–2.0 cases per million
population per year [1]. Although the diagnosis of malignan-
cy is easy in most cases, mainly due to advanced stage at
presentation, strictly intra-adrenal tumors must be evaluated
for malignant potential [2]. In this regard, several multi-
parametric scoring systems, including the Hough scoring
system, the Weiss scoring system, the Van Slooten scoring
system and the Weiss revisited index [3, 4], and, also
recently, diagnostic algorithms, such as the stepwise dis-
criminate diagnostic system and the simplified diagnostic
algorithm [5, 6], have been generated. The latter takes into
account the presence of a disrupted reticulin framework,
which constitutes the first step of this diagnostic approach, as
being the single most sensitive feature of malignancy. Other
parameters include mitotic count >5⁄50 HPF, presence of
necrosis and venous invasion [6].
Currently, the Weiss scoring system is the most
popular among multiparametric scoring systems, owing
to its reliability and relative simplicity (Table 1)[ 1, 7].
Nevertheless, the Weiss system suffers particular limitations
including (1) lack of reproducibility of several criteria, (2)
“borderline” tumors with a Weiss score of 2 or 3, (3–4)
oncocytic and myxoid variants of adrenocortical tumors and
(5) pediatric adrenocortical neoplasms [2, 7]. The latter are
frequently characterized by a limited malignant potential
especially in children<5 years of age, despite the presence of
impressively atypical histologic features (Fig. 1), which
could be attributed either to a low stage upon presentation or
to a putative origin from a cell of the fetal adrenal cortex [8].
The objectives of this review are (1) to present emerging
evidenceconcerningtheadrenocorticaltumorigenesisinorder
to address the issue of an adenoma–carcinoma sequential
progression as well as to further elucidate the incompletely
understood pathophysiology of this aggressive neoplasia and
(2) to describe in detail the rare variants of ACC to increase
awareness of their clinicopathological features and the
p o t e n t i a ld i a g n o s t i cc h a l l e n g e s .
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A hotly debated issue is whether or not adenomas progress
stepwise to carcinoma. Given (1) the differences between
benign and malignant tumors in terms of transcriptome and
genetic alterations, (2) the epidemiology of adrenal inci-
dentaloma and ACC and (3) the low incidence of
progression (5–25%) of clinically inapparent adrenal
masses to hyperfunction or an increase in size by at least
1 cm coupled with (4) the lack of clear evolution from
benign, non-secreting adenoma to ACC in untreated cases
[9, 10], it seems that multistep progression from benign to
malignant is unlikely for adrenal cortical neoplasms.
However, not all evidence points in that direction. Fewer
genetic aberrations were found in adenomas than in
carcinomas. Most (72–86%) distinct alterations seen in the
adenomas were also present in carcinomas [11, 12].
Furthermore, the positive correlation between the number
of alterations detected by comparative genomic hybridiza-
tion (CGH) and tumor size [11, 13] supports the notion of
an adenoma–carcinoma sequence. Additional evidence in
favor of such a sequence derives from X-chromosome
inactivation pattern analysis which shows monoclonal
ACCs along with ACAs of polyclonal or monoclonal
origin. Allelotyping with microsatellites and a few reported
cases provide support for an adrenal adenoma–carcinoma
sequence [14–20].
With regard to the latter, Bernard et al. [17]r e p o r t e do na n
intriguing case of a localized adrenal neoplasm composed of
two different components exhibiting different pathological
features: a central zone of a Weiss score (5) and a peripheral
zone of a Weiss score (0). The former zone displayed
complete LOH at the TP53 (17p13.3) gene locus, uniparental
disomy at the 11p15 locus, overexpression of the IGF-II
gene and numerous CGH changes, with gains at chromo-
somes 4, 5p, 10, 12p, 16p, 19 and 20 and losses at
chromosomes 2 and 11. The outer zone did not show any
of these genetic abnormalities. A similar case was presented
by Trezzi et al. [18] as a dedifferentiated adrenal cortical
neoplasm comprising a sharply outlined, hemorrhagic,
central nodule (ACC) and an outer ring zone (ACA), while
Gaujoux et al. [19] included one heterogeneous ACT in a
small series consisting of an ACC component (Weiss score
6) developed within an ACA component (Weiss score 1).
The malignant component exhibited diffuse cytoplasmic and
focal nuclear β-catenin accumulation and harbored a β-
catenin gene (CTNNB1) mutation, whereas the benign
component showed only focal cytoplasmic staining and no
such mutation. No TP53 somatic mutation was found in the
ACC and ACA components. Similarly, Schmitt et al. [20]
presented an ACA case showing frank heterogeneity both by
means of H&E staining (atypia, hyperchromasia, nucleoli
and atypical mitoses) and immunohistochemistry, including
perinuclear dot-like immunoreactivity for IGF-II, nuclear
staining for CDK4 and Ki67 labeling index > 5%. These
particular areas within the adenoma were interpreted as small
Fig. 1 Two areas from a pediatric adrenal cortical neoplasm,
weighing 88 g. Large, multinucleated tumor giant cells, with hyper-
chromatic nuclei and nuclear pseudoinclusions in a few, among
smaller tumor cells displaying high nuclear/cytoplasmic ratio and
hyperchromatic nuclei (a). Tumor cells with moderately atypical
nuclei and an atypical mitotic figure near the center of the field (b).
Despite these worrisome histological features, this neoplasm had a
benign biological behavior
Table 1 Weiss system for assessing malignant potential of adreno-
cortical neoplasms [2, 3]
Histological features to be evaluated
Diffuse architecture (greater than one third of the tumor)
Clear cells comprising 25% or less of the tumor
High nuclear grade (grade 3 or 4 according to Fuhrman criteria)
Mitotic rate ≥ 6 per 50 high-power fields
Atypical mitotic figures
Necrosis
Venous invasion
Sinusoidal invasion
Capsular invasion
The presence of three or more criteria highly correlates with malignant
behavior
10 Virchows Arch (2012) 460:9–18foci of malignant transformation, in accordance with a van
Slooten index > 8.
Whether the fact that different scoring systems yield
different diagnoses in individual ACTs [20, 21] points to a
multistep process remains to be clarified. It is tempting to
speculate that in a process of clonal evolution, one
dominant clone may overtake neighboring subclones to an
extent that the ACA component is no longer visible.
Recent evidence has suggested multistep tumorigenesis
within the group of ACCs [9]. In particular, transcriptome
analysis has established an ACC subclassification into two
distinct subgroups with different outcomes [22–24], con-
sistent with the notion that ACC survival and outcome vary
greatly mainly due to different molecular defects
modulating the tumor phenotype and, to a lesser extent,
to tumor stage at diagnosis [25]. However, ACCs in the
poor prognosis group displayed more advanced disease,
subsequently confounding the issue of whether these
subgroups correspond to distinct stages of the same
disease or to distinct ACC types. Statistical independence
of transcriptome-based prognostic information from stage
seems to argue in favor of the latter [26].
In an effort to further elucidate the molecular
genetics of the poor-outcome ACC group, Ragazzon et
al. [25] identified three subgroups by using unsupervised
clustering analysis: (1) p53 group, encompassing all
tumors with a TP53 mutation, (2) β-catenin group,
containing all tumors with beta-catenin nuclear staining,
and (3) x group, with neither p53 nor β-catenin altered
pathways, but enriched in cell cycle and metabolism
genes. Moreover, IGF-II overexpression has been shown
in approximately 90% of ACCs, with paternal unidisomy
and loss of imprinting being the underlying mechanisms
accounting for this markedly elevated expression in
familial ACC cases associated with Beckwith–Wiedemann
Syndrome, while additional mechanisms of transcriptional
regulation are likely to be involved in sporadic ACCs [9,
23]. In this context, Ragazzon et al. [25]d i dr e f e rt o
widespread IGF-II overexpression among both subgroups,
highlighting its importance in adrenocortical tumorigene-
sis, but concomitantly suggesting a role for additional
genomic alterations promoting the development of the
most aggressive tumors [25, 27]. Prior to IGF-II over-
expression, it appears that ACC loses nephroblastoma
overexpressed (nov) expression [28], in line with the
finding of a significantly reduced novH expresssion
correlated with the acquisition of a malignant tumoral
phenotype [29].
Several lines of evidence suggest that the activation of the
Wnt/β-catenin signaling pathway is important in adrenocor-
tical oncogenesis [19, 25, 30–37]. In fact, it has been
demonstrated that this activation, as assessed by abnor-
mal nuclear and/or cytoplasmic β-catenin accumulation
with or without somatic activating CTNNB1 mutations,
is involved both in benign and malignant adrenocortical
tumors [19, 31–33]. It is of particular interest to note that
CTNNB1 mutations (1) were detected only in macro-
nodules of primary pigmented nodular adrenocortical
disease cases, suggesting that these are secondary genetic
events contributing to the nodular development of the
disease and potentially implying a more aggressive
phenotype [19, 34], (2) were related to a specific
phenotype of larger and non-secreting ACAs, indicating
a less differentiated state [33], and (3) were associated with
decreased overall and disease-free survival in ACCs, suggest-
ing a specific effect on tumor biology in terms of progression
towards a more aggressive phenotype within the group of
ACCs [25, 35]. Altogether, these observations, along with
data stemming from an experimental mouse model [30], do
not completely clarify whether the activation of Wnt/beta-
catenin signaling pathway is an early or a late event in the
development of adrenal neoplasms.
Part II. Adrenocortical carcinoma variants
Oncocytic adrenocortical neoplasms
Oncocytic adrenocortical neoplasms (OAN) represent a rare
group of neoplasms with approximately 115 cases reported
in the literature [38–44]. Kakimoto et al. [38] first described
this particular histological variant in 1986, which was
followed by numerous reports either in the form of single
cases or of small series, with the largest one comprising 13
cases [39].
Accurate classification of OAN is important. Given that
OANs display (1) cells with eosinophilic cytoplasm, clear
cell population as a rule consisting of less than 25% of the
tumor volume, (2) high-grade nuclear atypia in at least a
subgroup of neoplastic cells and (3) almost always diffuse
architecture and since these inherent histological parameters
do not confer a poor prognosis [45], applying the Weiss
system to this subset of adenocortical neoplasms will lead
to a diagnosis of ACC, which is not appropriate given the
benign behavior of most of these lesions.
Bisceglia and colleagues [46] developed criteria for the
classification of oncocytic adrenocortical tumors (Table 2).
These were based on parameters of the Weiss system and
constituted the Lin–Weiss–Bisceglia (LWB) system: (1)
major criteria (a mitotic rate of more than 5 mitoses per 50
high-power fields, any atypical mitoses or venous inva-
sion), (2) minor criteria [large size (>10 cm and/or >
200 gr), necrosis, capsular invasion or sinusoidal invasion]
and (3) definitional criteria (predominantly cells with
eosinophilic-granular cytoplasm, high nuclear grade and
diffuse architectural pattern). The latter are not used as they
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and are not determinants of biological behavior. According
to the proposed working rules, the presence of any one of
the major criteria indicates malignancy (oncocytic adreno-
cortical carcinoma), and the presence of one to four minor
criteria is indicative of uncertain potential (borderline
oncocytic neoplasm of uncertain malignant potential)
(Fig. 2), while the absence of all major and minor criteria
indicates benign behavior (adrenocortical oncocytoma)
[46]. In addition, Bisceglia et al. [45] proposed categories
for oncocytic adrenocortical tumors as follows: (1) pure
oncocytic tumor, if a tumor is exclusively or almost entirely
composed (greater than 90%) of oncocytic cells, (2) mixed
oncocytic tumor, when a clear cell component is also
present (ranging from 10% to 50%), and (3) ordinary
adrenocortical tumor with focal oncocytic changes, if the
oncocytic component is not a predominant one (less than
50% of the tumor mass).
It is critical to extensively sample an oncocytic adreno-
cortical neoplasm for several reasons. First, one should
discriminate a pure oncocytic tumor either from an ordinary
adrenocortical tumor with focal oncocytic changes or its
conventional counterpart of the compact cell type in order
not to incorrectly apply the Weiss system and accordingly
inadequately estimate its biological behavior [45]. Second,
an oncocytic tumor can only be labeled as pure after
quantifying each individual component (oncocytic and
clear) since pure and mixed oncocytic tumors do not seem
to share similar clinical outcome [45]. In this regard,
immunohistochemistry using antimitochondrial antibodies
can support the recognition of oncocytic differentiation and
help to accurately quantify the oncocytic component. Of
note, adrenocortical cells are, by nature, rich in mitochon-
dria and therefore positive, so only strong, diffuse and
finely granular staining should be taken as indicative of
oncocytic differentiation, as suggested by Wong et al. [39]
with respect to mES-13 staining. Moreover, the differential
diagnostic spectrum of OANs also includes the oncocytic
variant of pheochromocytoma, the granular cell variant of
clear cell renal cell carcinoma, the eosinophilic variant of
chromophobe renal cell carcinoma and the hepatocellular
carcinoma [45, 46].
In an effort to further delineate and elucidate this subtype
of adrenocortical neoplasia, Wong et al. [39] provided a
comprehensive review and retrospectively applied the LWB
criteria to all reported cases with sufficient information,
along with 13 previously unpublished cases. Of note, they
validated the effectiveness of the LWB criteria in predicting
malignant potential and provided preliminary evidence
supporting the concept of a more favorable prognosis for
oncocytic adrenocortical carcinomas in comparison with
their conventional counterparts. Moreover, they found
approximately 30% of OANs to be functional while
emphasizing the frequency of small oncocytes in several
cases of their series [39], accordingly including in their
view of the oncocyte not only cells with abundant granular
eosinophilic cytoplasm.
Myxoid adrenocortical neoplasms
In keeping with the current notion that myxoid extracellular
matrix is a histological feature that can be found in both
physiological and pathological conditions, non-neoplastic
(e.g. myxedema) as well as neoplastic (benign/malignant
epithelial or mesenchymal tumors) [47], myxoid change has
been recognized rarely also in neoplasms of adrenal cortical
origin. The myxoid substance has been shown to be Alcian-
blue positive and negative or focally weak positive for PAS
Fig. 2 Section of an oncocytic adrenocortical neoplasm, weighing
>200 g; in the presence of only one minor criterion (according to the
Lin–Weiss–Bisceglia classification), a diagnosis of borderline onco-
cytic neoplasm of uncertain malignant potential was finally rendered.
Diffuse growth pattern of tumor cells, characteristically displaying
abundant eosinophilic, granular cytoplasm and at least focal high
nuclear atypia. Marked degree of nuclear pleomorphism (inset). These
would lead to a Weiss score 3, probably overestimating the biological
behavior of this lesion
Table 2 Lin–Weiss–Bisceglia (LWB) system for diagnostic categori-
zation of oncocytic adrenocortical neoplasms [42]
Major criteria
Mitotic count >5 per 50 high-power fields
Atypical mitoses
Venous invasion
Minor criteria
Size >10 cm and/or weight >200 g
Necrosis
Sinusoidal invasion
Capsular invasion
The presence of one major criterion indicates malignancy, one to four
minor criteria present indicates uncertain malignant potential, and the
absence of all major and minor criteria is indicative of benign
biological behavior
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far 46 reports of myxoid adrenocortical neoplasms (MANs)
[48–65]: 17 myxoid adrenocortical adenomas [49–58], 2
borderline MANs [48, 50] and 27 myxoid adrenocortical
carcinomas [48, 49, 59–65]. These cases were either
published as isolated case reports or were presented in
small series, with the largest ones each consisting of 14
cases [48, 49].
The reported age range of MANs (46 cases) is 16 to
82 years, with a mean and a median age of 51 and 51.5 years,
respectively. In general, cases in females slightly outnumber
those in males (26:20). Hormone hypersecretion occurs
frequently in these tumors; only 13 out of 42 cases were
non-functioning (eight adenomas, one borderline and four
carcinomas), whereas five patients had biochemical evidence
of hormone production (two adenomas, one borderline and
two carcinomas). The remaining 24 cases with an available
endocrine evaluation presented with clinical evidence of
hormone overproduction: 16 withCushing-related symptoms,
4 with Conn syndrome, 2 with symptoms due to cortisol and
androgens, 1 with gynecomastia and breast pain and 1 with
virilization (4 adenomas and 20 carcinomas). Although it had
been suggested that the functional status could be associated
withthe presenceofmyxoidmaterial,non-functioning tumors
displaying a higher percentage of myxoid areas and being
lipiddepleted[61], no definite conclusions can be reached on
morphological grounds. In fact, eight cases showing a
myxoid area > 70 % were hormonally active [48–50, 62,
63], whereas another eight cases with a similar myxoid
content were non-functional [48, 51, 53–55, 57, 59, 60]. The
proportion of myxoid change varied in all reported cases
from 5% to approximately 100% of the total area.
Interestingly, neurofilament (NF) expression has been re-
cently found to be related more to the extent of myxoid
changes and, therefore, suggested as a potential characteristic
of myxoid ACCs with a predominant (> 70 %) myxoid
component [48]. This, along with the fact that the
expression of neuroendocrine/neuronal markers such as
NF and CD56 was mostly restricted to the myxoid areas
of conventional ACCs with focal myxoid change,s e e m st o
imply a peculiar association between NF expression and
myxoid change [48].
An important point is the distinction of myxoid
borderline/malignant ACTs into two subgroups as
proposed by Papotti et al. [48]: myxoid ACCs and
conventional ACCs with focal myxoid changes.T h i si s
based on a different type of myxoid change, growth
pattern, cell size, nuclear atypia and cell cytoplasm.
Myxoid ACCs are usually characterized by (1) extensive
myxoid areas separated from conventional ACC areas, if
present, (2) trabecular/microacinar growth pattern, (3)
small, uniform cell size, (4) mild nuclear atypia and (5)
scant, eosinophilic cell cytoplasm, whereas conventional
ACCs with focal myxoid changes are characterized by (1)
focal myxoid areas (< 20% of the total area) always
merging with conventional ACC areas, (2) solid/diffuse
growth pattern, (3) large, heterogenous cell size, (4)
moderate to high nuclear atypia and (5) abundant, granular
eosinophilic cell cytoplasm. Nevertheless, two cases of the
former subset showed overlapping features such as solid
growth pattern and pleomorphism as well. In addition, the
same investigators [48] suggested that only the former
subgroup actually belongs to the distinctive myxoid
variant of ACTs, with the latter potentially representing
the result of myxoid degenerative changes (Fig. 3).
Whether or not these subgroups have a distinct biologic
behavior needs to be further elucidated.
In the histopathological assessment of these lesions, it
is critical first to exclude potential morphological
mimics, including metastatic tumors affecting the adrenal
gland (breast carcinomas, salivary or skin adnexal carci-
nomas of adenoid cystic type and neuroendocrine tumors)
[48]a sw e l la sp r i m a r yretroperitoneal neoplasms with
myxoid areas (chordomas, myxomas, lipomas or liposarco-
mas, leiomyomas or leiomyosarcomas, benign or malignant
nerve sheath tumors, extraskeletal myxoid chondrosarcomas,
gastrointestinal stromal tumors and myxoid malignant
fibrous histiocytomas) [49, 50, 63]. The presence of
typical foci of adrenocortical differentiation, along with an
immunohistochemical profile similar to that of the
conventional ACT, provides valuable aid in excluding
these mimics [48, 50, 51]. In addition, accurate assessment
of malignant potential in any given tumor of the myxoid
variant is important. In this regard, the issue of whether
the Weiss scoring system is adequate to reliably predict
malignancy in MANs is currently being questioned
because:
(1) AMANcaselackingmorphologicalsignsofmalignancy
(Weiss score 1/clear cell cytoplasm present in less than
25% of the tumor cells) and diagnosed as myxoid
borderline ACT [59] subsequently did demonstrate an
aggressive clinical behavior (peritoneal spread), with a
dismal outcome 68 months following the initial
diagnosis [48]. Another such tumor of uncertain
malignant potential (Weiss score 1/clear cell cytoplasm
present in less than 25% of the tumor cells) has been
recently described by the same group, with no evidence
of recurrence or metastasis 9 months following surgical
resection. Both cases were characterized by the same
extent of myxoid area (90%), growth pattern, Weiss
score and low Ki67 labeling index (3% and 4%,
respectively). Interestingly, the latter case had an intact
reticulin network as opposed to the former, which
displayed stromal framework disruption as confirmed
by the reticulin stain [48].
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mitoses 3/10 HPFs, mild to moderate nuclear pleo-
morphism, cells with ample predominantly eosino-
philic cytoplasm, occasional clear cells and a tumor
weight of 94 g) did not recur or metastasize after a
follow-up period of 18 months [50]. In addition, four
out of six myxoid ACAs reported in a series by Brown
et al. [49] were large (≥ 6 cm), showed focal capsular
invasion and a mitotic activity of ≥ 1/10 HPFs in the
absence of recurrence or metastatic disease after a
mean follow-up period of 12 years. It should be
stressed that 9 out of 17 myxoid ACAs were relatively
large (≥ 6 cm), a feature further challenging the
prediction of a benign clinical course [49, 50, 54–57].
(3) Some of the Weiss score parameters were hard to
assess in the myxoid areas, while others could be
identified in a variable percentage according to
observations made by Papotti et al. [48] in the subset
of myxoid ACCs. In particular, diffuse growth pattern
was never a feature, atypia was minimal or absent, and
small vessel invasion was less apparent due to myxoid
areas in contrast to necrosis, “dark” cell cytoplasm and
mitotic figures which were the only readily apparent
criteria. In keeping with this, Hsieh et al. [62] reported
on a myxoid ACC showing an extensive myxoid area
(80% of the tumor area) of Weiss score (3) and a non-
myxoid component of Weiss score (6); the latter
consisted of three growth patterns (trabecular, solid
and clear cell), each exhibiting different Weiss score
parameters. Moreover, Brown et al. [49] noted that
mitoses, when present, were generally less frequent in
myxoid areas, while extensive extracapsular involve-
ment was a feature only of carcinomas.
Adrenocortical carcinomas with a sarcomatous
or sarcoma-like component
According to WHO classification 2004, oncocytic ACCs,
myxoid ACCs and ACCs with sarcomatous areas are
regarded as rare variants of ACC [66]. Whether the latter
variant should be designated carcinosarcoma or sarcoma-
toid carcinoma, as previously suggested by Sturm and
colleagues [67] in agreement with the WHO terminology
applied to biphasic tumors with pleomorphic, sarcomatous
or sarcomatoid elements arising in other organs [68], is still
unsettled. Nevertheless, nine cases of this unusual variant
have been previously reported [67, 69–76], with only four
corresponding to true carcinosarcomas [69, 72–74], consis-
tent with the concept that carcinosarcomas are tumors
composed of morphologically malignant epithelial and
specialized mesenchymal elements, easily recognizable
histologically as forms of mesenchymal malignancy resem-
bling osteosarcoma, chondrosarcoma, rhabdomyosarcoma,
angiosarcoma or liposarcoma (Fig. 4)[ 77]. Adrenal
carcinosarcomas, like their counterparts in other organ
systems, were mainly characterized by a rhabdomyosar-
comatous component (three out of four) [69, 73, 74], while
only one case was characterized by a mixture of osteosar-
Fig. 3 Section of a myxoid
adrenocortical carcinoma show-
ing a necrotic area at the right of
the field (a). Tumor cells are
arranged in a small nested (b)o r
trabecular/cord-like (c) growth
pattern focally displaying
marked nuclear atypia (b–c).
Area of conventional adreno-
cortical carcinoma (60–70% of
total area in histologic sections);
neoplastic cells are arranged in
an interanastomosing trabecular
pattern showing severe nuclear
atypia near the center of the
field (d)
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biphasic cases without heterologous elements did have a
spindle cell component [67, 70, 71, 75, 76], with three out
of five also showing variably giant cells in the sarcomatous
component [67, 70, 75].
Another unique malignant biphasic neoplasm arising as a
primary tumor of the adrenal gland is the adrenocortical
blastoma. This functional (virilizing) malignant tumor has
been reported in an infant, and it consisted of a mixture of
immature epithelial and mesenchymal elements, along with
slit-like spaces partially lined by primitive epithelial cells,
focally recapitulating the morphology of the normal
embryologic development of the adrenal cortex [78]. There
have been no additional cases reported, and therefore, the
question whether this neoplasm is indeed restricted to the
pediatric age group [79] similar to pleuropulmonary
blastoma (virtually restricted) but in contrast to pulmonary
blastoma [77] remains unresolved.
Of interest, only two out of four carcinosarcomas
were functional, presenting with clinical signs either of
hyperaldosteronism or of virilization [72, 73], whereas
all adrenocortical sarcomatoid carcinomas were non-
functioning [67, 70, 71, 75, 76].
Although the limited number of reported cases does not
allowanydefiniteconclusion,adrenocorticalcarcinosarcomas
and sarcomatoid carcinomas have similar clinical outcome
(postoperative survival ranging from 2 days to 12 months;
median 6 months) [69] and therefore have a worse prognosis
than their conventional counterparts [67]. This dramatically
aggressive behavior may be attributed not only to advanced
stage at presentation but also in part to inherent biological
properties potentially deriving by progression (dedifferenti-
ation) from a pre-existing better differentiated ACC, in
analogy to the undifferentiated (anaplastic) carcinoma of the
thyroid gland [66, 80]. This endows cells with migratory and
invasive properties, epithelial-mesenchymal transition, stem-
ness, prevention of apoptosis and senescence, and it
contributes to immunosuppression and notably confers
resistance to chemotherapy and immunotherapy [81].
Although various theories have been proposed with regard
to the histogenesis of carcinosarcomas, namely (1) the
composition tumor theory (paradoxically requiring a non-
malignant non-epithelial component as a reactive prolifera-
tive response induced by the epithelial component via
paracrine secretion), (2) the collision or biclonal tumor
theory (a collision between two synchronous, histogeneti-
cally independent, biclonal tumors), (3) the conversion tumor
theory (neoplastic transformation within a monoclonal tumor
recapitulating the naturally occurring event of conversion of
epithelial to mesenchymal cells during embryogenesis) [81]
and (4) the combination or divergent tumor theory (deriving
from a common monoclonal stem cell precursor) [82–85],
molecular genetic evidence of monoclonality supports the
single pluripotential stem-cell-divergence hypothesis and the
epithelial-to-mesenchymal transition as well [83–85]. With
regard to ACCs with sarcomatous areas, evidence emerging
from the immunophenotypical profile of the sarcomatous
component (focal retaining of Melan-A, synaptophysin and
Fig. 4 Sections of an adreno-
cortical carcinosarcoma com-
prising a well-differentiated
carcinomatous component (a)
and a sarcomatous component
demonstrating osteosarcomatous
differentiation (b) along with
areas of uniform spindle cells
arranged in a fascicular (c)o r
herringbone (d) growth pattern
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(intermingled) zones between carcinomatous and sarcoma-
tous components [67, 70, 73] seem to imply such a putative
transition. Differences of the mitotic count in the distinct
elements [7/10 HPF (epithelioid component) versus 30/10
HPF (pleomorphic/spindle cell component)] [69] and the
presence only of the sarcomatous component either in large
veins into the periadrenal fat [67] or in well-established
metastases [71, 74] are consistent with a dedifferentiation
process.
Aberrant phenotypical differentiation observed in this
particular variant includes both neural and melanocytic
differentiation (NSE, S100 and HMB-45 immunoreactivity)
[70, 71]. Although melanocytic differentiation, suggestive
of a divergent evolutionary pathway, has been reported in
carcinosarcomas of other anatomic locations [86–89],
pathologists should always keep in mind to first exclude
the possibilities of a metastatic melanoma, a collision tumor
consisting of an ACC and a primary or metastatic
melanoma (not yet reported) and a primary perivascular
epithelioid cell tumor [90]. Other differential diagnostic
considerations include composite pheochromocytoma with
a malignant peripheral nerve sheath tumor component (the
latter with or without divergent differentiation into mesen-
chymal elements such as rhabdomyo-, osteo-, chondro-,
angio- and/or fibro-sarcomatous components) [91, 92],
metastatic carcinoma with sarcomatous or sarcoma-like
areas and metastatic neoplasm with sarcomatoid elements
other than carcinomas (melanoma or germ cell tumor), as
well as primary retroperitoneal sarcomas [69]. Given that
adrenal biphasic tumors, in contrast to those arising in
epithelial organs, are unlikely to express cytokeratins while
focal smooth muscle differentiation is a common finding,
thorough sampling of the resected tumor is of critical
importance in order to reveal the co-existent carcinomatous
component and subsequently prove the adrenal origin on
immunohistochemical grounds [67, 69].
SinceACCswith sarcomatous areas are highly aggressive
tumors and a sarcomatous or sarcomatoid component seems
to be a predictor of shorter survival in ACC, the question
arises whether the Weiss scoring system should be applied to
this extremely rare ACC variant. In fact, ACCs with
sarcomatous areas regroup the majority of Weiss histolog-
ical criteria [67]. In this setting, Sturm and colleagues [67]
have proposed that a sarcomatous or sarcomatoid component
should be well circumscribed and represent at least 10% of
the tumor bulk to establish this unusual diagnosis. Never-
theless, the sarcomatous or sarcomatoid component is not
included in the Weiss system, further confounding this issue
when dealing with a biphasic tumor demonstrating a
predominant non-carcinomatous component [67, 69]; in such
cases, the criterion of diffuse architecture (greater than 1/3) is
being obviously challenged.
Conclusion
In summary, we discussed the issue of multistep tumorigenesis
in adrenocortical neoplasia and provided an overview of the
ACN variants in order to make histopathologists aware of the
clinicopathological spectrum. It is important to correctly
characterize their biological potential, which is occasionally
not an easy task for myxoid and oncocytic adrenocortical
tumors. In this context, applying the Weiss scoring system on
the latter would definitely tilt the diagnostic balance towards
malignancy in a similar way as pediatric ACNs (pathologically
malignant but benign-behaving tumors) [8], whereas under-
diagnosis could potentially be the case with regard to the
myxoid ones. In this setting, even the multistep tumorigenic
processes are hard to take apart and analyze, while evidence
for a distinct biological behavior is either preliminary [39]o r
unestablished [48] due to the small number of reported cases,
limited follow-up period, insufficient data and heterogeneity.
Whenever pathologists report on these variants singly or as
part of larger series, it is recommended to note the diagnostic
subcategory, as has been previously suggested (pure oncocytic
tumor/mixed oncocytic tumor/ordinary adrenocortical tumor
with focal oncocytic changes, myxoid ACCs/conventional
ACCs with focal myxoid changes and carcinosarcoma/
sarcomatoid carcinoma) [39, 48].
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